Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cardiol Therapeutics ( (TSE:CRDL) ) has provided an update.
Cardiol Therapeutics Inc., a late-stage life sciences company focused on anti-inflammatory and anti-fibrotic therapies for heart disease, is advancing its lead candidate CardiolRx to treat recurrent pericarditis and acute myocarditis, supported by the MAVERIC and ARCHER clinical programs, and is developing CRD-38 for inflammatory heart disease including heart failure. The U.S. FDA has granted Orphan Drug Designation to CardiolRx for pericarditis, underscoring the company’s positioning in serious cardiovascular conditions with significant unmet need.
On April 14, 2026, Cardiol announced that President and CEO David Elsley would appear in a live interview on X with Barchart to discuss the ongoing pivotal Phase III MAVERIC trial in recurrent pericarditis, the recently published Phase II ARCHER results in acute myocarditis, and progress with CRD-38. The interview, scheduled for noon EDT and to be made available in full afterward on the company’s and Barchart’s X channels, aims to spotlight the company’s late-stage pipeline and clinical momentum for investors and other stakeholders.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$8.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on CRDL Stock
According to Spark, TipRanks’ AI Analyst, CRDL is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, sizable losses, and sustained cash burn), partially offset by a low-debt balance sheet. Technicals are a positive contributor with an improving uptrend and constructive momentum, while valuation remains constrained due to negative earnings and no dividend support.
To see Spark’s full report on CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a late-stage life sciences company listed on NASDAQ and the TSX that develops anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead small-molecule candidate, CardiolRx, targets inflammasome pathway activation in conditions such as recurrent pericarditis, acute myocarditis, and heart failure, and it is also advancing a next-generation subcutaneous drug, CRD-38, for inflammatory heart disease.
Average Trading Volume: 123,682
Technical Sentiment Signal: Buy
Current Market Cap: C$215.9M
For a thorough assessment of CRDL stock, go to TipRanks’ Stock Analysis page.